Neil Riordan, PA, PhD Presents at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, UT on Thursday, February 28th

Neil Riordan, PA, PhD presented “Results From Panama Clinical Trials Using Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (HUCT-MSCs) for Multiple Sclerosis and Autism” at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, UT on Thursday, February 28th.

Image of Neil Riordan, PA, PhD

Neil Riordan, PA, PhD

SALT LAKE CITY (PRWEB) MARCH 01, 2019

Neil Riordan, PA, PhD presented “Results From Panama Clinical Trials Using Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (HUCT-MSCs) for Multiple Sclerosis and Autism” at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, UT on Thursday, February 28t.

During his talk, Dr. Riordan discussed his recently published phase I/II clinical trial entitled, “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis”.

“It was an honor to speak with my distinguished peers on the advances of stem cell therapy in perinatal medicine today,” Neil H. Riordan, PA, PhD

https://www.ncbi.nlm.nih.gov/pubmed/29523171

He also touched on his recently completed and soon-to-be-published phase 1/II clinical trial on autism, “Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism” (NCT02192749).

About Perinatal Stem Cell Society

In 2013, the International Perinatal Stem Cell Society, Inc. a non-profit (501(c)(3) organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders. Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/wharton’s jelly, as well as placental blood and placental tissue. Perinatal stem cells are formed around the time of birth and are classified as adult stem cells but they really are more primitive then stem cells found in bone marrow or adipose tissue or other traditional sources of adult stem cells and as such, have greater therapeutic potential.

Learn more at http://www.perinatalstemcells.com

About Riordan Technologies

Riordan Technologies strives to improve the human condition through innovation in scientific research, regenerative medicine, and stem cell therapy. Riordan Technologies comprises companies founded by Neil Riordan, PA, PhD: Dallas-based Aidan Products, Signature Biologics, and Riordan Medical Institute, and Panama-based Stem Cell Institute and Medistem Panama.

Read Dr. Riordan’s Amazon #1 Best Seller: Stem Cell Therapy: A Rising Tide – How Stem Cells Are Disrupting Medicine and Transforming Lives

Learn more at at http://www.neilriordan.com

Stem cell pioneer sets sights on Japan – Japan Times features Neil Riordan, PhD of Medistem Panama

Japan Times Article Medistem

“We enjoy the advantage of having a large amount of clinical data on 2,000 patients. So we analyzed who received which cells and which cells worked best in different conditions. This allowed us to create our selection process through molecular profiling,” explained Medistem (Panama) Founder and CEO Dr. Neil Riordan.

Operating what is arguably the country’s most advanced laboratory, an 8,000-sq-ft facility in the City of Knowledge science and technology cluster, Medistem has raised its profile in recent years as it develops stem cell-based products for clinical trials for treatment of autism, asthma, multiple sclerosis, osteoarthritis, rheumatoid arthritis and spinal cord injuries.

Utilizing its patented technologies, Medistem harvests human adult stem cells from umbilical cords, tissues and blood as well as from bone marrow and adipose tissue. “We have intellectual property on a methodology for basically defining which are good cells, which are mediocre and which are the useless ones. The U.S. Food and Drug Administration has approved our cells for compassionate use in the United States. This is a big step,” Riordan said.

Compassionate use, also known as expanded access, refers to the use of investigational new drugs outside of a clinical trial by patients with serious, life-threatening conditions. After finishing its first prospective clinical trial, and with six others in the pipeline, the company is considering the favorable regulatory conditions for cell therapy in Japan, now a promising market for its products.

“Japan has a law on the books that allows a company of our size to commercialize such products. That makes it our number one priority. We are gearing up to present our data to regulators, as well holding talks with potential partners over there,” Riordan added.

The Lip TV News: Neil Riordan, PhD on Exploring New Stem Cell Treatments for MS, Arthritis, Autism and More

Stem cell treatment and research towards curing illness–from multiple sclerosis to spinal injury–is detailed by Dr. Neil Riordan. The American medical industry, obstructions to research in the states, misconceptions about stem cells, and the details about the treatment process are explained–and we look at video of patient recovery and speculate at what the future could spell for stem cell treatment and research in this Lip News interview, hosted by Elliot Hill.

GUEST BIO:
Dr. Neil Riordan is the founder and Chairman of Medistem Panama, a leading stem cell laboratory and research facility – located in Panama City. His institute is at the forefront of research of the effects of adult stem cells on the course of several chronic diseases. Dr. Riordan has more than 60 scientific articles in international peer-reviewed journals. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis.

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.

San Antonio, TX (PRWEB) September 11, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.
Stem Cell Institute Speakers include:

Neil Riordan PhD – “Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols”
Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD
– “Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries”
Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special Guest Speaker:
Janet Vaughan, DDS, MS, Professional Dancer – “Successful Stem Cell Therapy in Panama: A Patient’s Perspective”
Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.

She is a U.S. national Dance Sport Champion, currently holding national titles in 16 divisions of ballroom dancing including numerous gold medals. She was previously the #1 Pro/Am Ballroom Dancer in the United States.

Light snacks will be served afterwards. Our speakers and stem cell therapy patients will be on hand to share their personal experiences and answer questions.

Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-san-antonio-tickets-12029022129 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.

About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include heart disease and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Website: http://www.medistempanama.com

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences Web Site: http://www.translationalbiosciences.com

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014

New York, NY (PRWEB) April 09, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Speakers include:

Neil Riordan PhD“Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury”

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD“Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus”

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.

Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.

About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.

To-date, SCI has treated over 2000 patients.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences webSite: http://www.translationalbiosciences.com

Email: trials(at)translationalbiosciences(dot)com

5 year-old autistic boy making steady gains after umbilical cord stem cell treatments

The names in this interview have been changed at the parents’ request to maintain privacy.

The following is a transcription of an interview with A.R. and S.R. regarding their son “Billy”. “Billy” was diagnosed Autism Spectrum Disorder (ASD) just before his second birthday in February 2011. Since that time, “Billy” has received several courses of human umbilical cord-derived mesenchymal stem cells at the Stem Cell Institute.

“In general, his improvements have been so great that the school is advising a repeat assessment to see if he still fits under the diagnosis of ASD.”

What kind of ASD symptoms did “Billy” have before his stem cell treatments?

His symptoms included temper tantrums that resembled seizures lasting 30 to 45 minutes at a time. He was hyperactive and sometimes unintentionally violent in his play. He had very poor eye contact. He did not answer to his name. His dietary habits were very limited.

How has “Billy” improved since his last round of treatments?

Thus far, he has had three Rx cycles at the Center: July, 2012 (age 3y-4mo), March 2013 (age 4y) and Feb 2014 (age 4y, 11 mo). Each time he showed rather sudden improvements in almost all areas of prior difficulties. After his first treatment, 90% of the tantrums disappeared within two weeks. His eye contact suddenly improved. He became much more aware of his surroundings – almost as if he just woke from a half sleep state. He started playing with his father for first time and with his twin somewhat. Transitions were much easier. Speech improved. He started greeting his therapists by name each day. We did not tell the therapists of the stem cell Rx as we wanted to get an unbiased feedback on his progress. They were rather surprised at the sudden change in his cognition and behavior. He still had some issues like not initiating play with his twin or other kids. His eye contact was much improved but not quite the same level as expected of his age group. Reciprocal conversation was also limited. After his second Rx he started to initiate play with his sib and other kids. Tantrums completely disappeared. Transition issues and general parental compliance improved. He started attending JK class in Sept 2014. He was assessed by a clinical psychologist for his post IBI evaluation in Oct 2014. Overall, he had showed considerable improvements, especially in non-verbal learning abilities as these were now on par as expected for normal kids his age (45’th percentile). However, his verbal learning abilities remained compromised (8’th percentile). His main limiting factors were his attention span and his diet remained somewhat limited. After his third Rx in Feb 2014, we have thus far noticed remarkable improvement in his diet. He is now eating sometimes even better than his normal twin. His language seems to be further along with more complex sentences. Hyperactivity and focus has also improved and we are only one month post Rx at the time of writing of this feedback. In general, his improvements have been so great that the school is advising a repeat assessment to see if he still fits under the diagnosis of ASD. We are awaiting an appointment for this some time later this year.

What kind of treatments and/or therapies did you try before coming to Panama for stem cell therapy?

Following the diagnosis, we attended parental workshops to help these types of kids with speech and other developmental issues. We began taking him daily to Ontario Early Years centers where “Billy” could be exposed to other normal kids his age group so can join in on children’s activities. His speech improved a bit with this exposure. However, he would not play with the other children. Nine months after his diagnosis, he was accepted into the Themes Valley Autism Treatment program. They started sending in IBI therapists to work with “Billy” for about 6 hours per weekday. He made a little bit further progress in language but eye contact remained extremely poor. Temper tantrums were still a major issue. Transitions remained very difficult. Diet remained very limited. He did not play with his normal (non-identical) twin or other kids.

How did you find the clinic and what made you decide upon the Stem Cell Institute?

We found the Panama clinic by researching for additional modalities of treatment. We reviewed some of the candid discussions and videos of families of former patients of the clinic. We queried the medical officers at the clinic to ensure cell samples were screened thoroughly for blood borne pathogens. We finally decided to go ahead with the treatment as “Billy” clearly would not have had a very happy life if we continued with only behavioral therapy. We also were afraid he may unintentionally harm his normal twin due to his sudden violent movements and outbursts.

Stem Cell Institute Company Logo

Umbilical cord mesenchymal stem cell therapy for PDD-NOS (Autism spectrum)

The Mendez family discusses their son’s progress following several rounds of stem cell therapy at the Stem Cell Institute. They’ve requested that we not use their first names in order to maintain privacy.

“He is a different child than he was before we started the treatments, and everyone is amazed at how well he is doing. We are grateful to God for helping us to find this treatment because now we can see our son being fully recovered.”

What is your son’s diagnosis?

Our son was diagnosed with severe apraxia, developmental delay, and PDD-NOS

What symptoms did he have before coming for stem cell treatment?

At six years old, he had a very short attention spam and very little speech. He had a lot of constipation and problems with balance and coordination. We were extremely concerned.

What did you try in the US before seeking help outside the country?

We tried everything with our son. He was treated by a DAN Doctor and we did many biomedical treatments. He was doing intense speech therapy and many hours of Hyperbaric Oxygen Therapy, but he still had very little speech and we were very frustrated with the lack of progress.

Why did you choose the Stem Cell Institute?

After doing a lot of research and talking to other parents who had success with Stem Cell treatment for their children, we decided we needed to try. We choose the Stem Cell Institute because we spoke to other parents who had great results and read about their research. We also went to their conference in Texas.

How were the doctors at the clinic?

The doctors at the clinic were very knowledgeable and professional. The clinic was impeccable.

How are your son’s symptoms now?

After our son’s stem cell treatments, he has improved tremendously. He has a great attention span and has gained a ton of speech. He is no longer constipated and the improvements keep coming. We saw huge improvements in just weeks after the stem cell treatments that we never saw with years of Biomedical treatment and speech therapy.

When did you start noticing a difference?

We say improvements just after two weeks.

How has this changed your lives?

This treatment has changed our lives significantly. Our son is able to speak in sentences and express himself. He can sit and eat at a restaurant and has absolutely no problems with attention. He is a different child than he was before we started the treatments, and everyone is amazed at how well he is doing. We are grateful to God for helping us to find this treatment because now we can see our son being fully recovered. We are very thankful to everyone at the Stem Cell Institute for the amazing job they are doing.

The Mendez Family

Stem Cell Therapy for Autism – Ethan’s Journey

We received this message yesterday from Sean and Sarah Collins on Facebook regarding their son Ethan who suffered a mild traumatic brain injury and has symptoms of PDD-NOS and ADHD.

Hi all!

I wanted to update you on Ethan. He is doing fantastic! His cognitive flexibility has dramatically improved. We have reduced another medication and eliminated 2 major medications since we started last April. I have created a FB page if you want to check it out. Thank you so much for helping us get our little boy back!

Sean and Sarah Collins
Stem Cell Therapy for Autism Ethan’s Journey

PDD-NOS stands for Pervasive Developmental Disorder-Not Otherwise Specified. Psychologists and psychiatrists sometimes use the term “pervasive developmental disorders” and “autism spectrum disorders” (ASD) interchangeably. …more information about PDD-NOS

NIH Awards Stem Cell Grant for the Study of Autism

The National Institutes of Health (NIH) have announced the awarding of a $3 million grant to Children’s Hospital of Orange County (CHOC) in California to study stem cells in autistic children.

More specifically, ordinary fibroblasts (skin cells) will be derived from the autistic children, which will then be reprogrammed and de-differentiated into iPS (induced pluripotent stem) cells which in turn will be re-differentiated into neural cells. Scientists hope that properties of the neural cells will shed some light on the unique characteristics of autism, thereby ultimately leading to more efficacious forms of treatment for the disorder.

Funding from the NIH grant is to be distributed over 5 years and will result in the first repository of neural cells derived from living patients. Prior to the recent development of iPS technology, the only way to derived neural cells from someone was via autopsy after death. Now, however, any living person can easily donate an ordinary skin cell, which, from the intermediate stage of an iPS cell, can be reprogrammed into virtually any type of cell found within the human body.

The grant was awarded through the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The specific recipient of the grant at CHOC is the National Human Neural Stem Cell Resource program, and the award constitutes the largest federally funded basic science research grant that any department within CHOC has ever received.

According to Dr. Philip Schwartz, principal investigator and founding director of the National Human Neural Stem Cell Resource at CHOC, "This is a completely novel approach to studying the neurobiology of autism and the first time we’ll be able to do so with neural cells actually derived from large numbers of children living with the condition. We hope to confirm over the next several years that neural cells generated from these donated fibroblasts can provide a viable experimental model that will yield insights about the origins, diagnosis, and treatment of autism."

Autism spectrum disorders (ASD) constitute the fastest growing developmental disability in the United States, with approximately one child in every 150 being diagnosed with some form of ASD. According to the Autism Society of America, the rate of diagnosis increases between 10 and 17% every year. Although an indisputable, definitive etiology has not yet been proven, a certain amount of controversy continues to surround ASD, as a growing amount of evidence seems to implicate environmental causes as the initiating trigger of ASD, especially heavy metals such as the mercury that is traceable directly to thimerosal. Also known as sodium ethylmercurithiosalicylate (C9H9HgNaO2S), thimerosal was originally developed as an antiseptic and antifungal agent but continues to be routinely used as a preservative in childhood vaccines. The controversy surrounding thimerosal, however, and its possible link to autism, has resulted in the gradual phasing out of thimerosal in the U.S., the European Union and a few other countries. Nevertheless, by 2007 it was estimated that more than 5,000 families in the U.S. have filed claims in a federal vaccine court alleging that their children became autistic as a result of having been vaccinated with thimerosal-containing vaccines. Although most of the cases are still being adjudicated, the U.S. federal government did award damages in one case, to the family of a young girl with the pre-existing condition of mitochondrial enzyme deficiency, who subsequently developed autism after receiving a series of thimerosal-containing vaccines. Many parents regard this ruling as confirmation that thimerosal is indeed a cause of autism.

A number of prominent scientists have researched the autism-vaccine connection extensively, perhaps the most notable of whom was Bernard Rimland, Ph.D., of San Diego, who founded the Autism Society of America in 1965 and who also founded the Autism Research Institute (ARI) in 1967, which he directed until his death from cancer in 2006. Inspired by his autistic son, Mark, who was born in 1956 when autism was quite rare, Dr. Rimland dedicated the remainder of his life to finding a scientific explanation and cure for the disorder. After more than 40 years of research, he became increasingly convinced that the causes of autism can be traced directly to the increasing number of vaccines that are prescribed in childhood. Dr. Rimland was one of the first scientists to correlate the increasing number of autism diagnoses per year to the presence of mercury in vaccines, pointing out that in 1990 autism was diagnosed at a frequency of one child per every 10,000 (ten thousand) children, whereas by 2004 the frequency had risen to one child per every 150 children, which represents an increase of 6,670%. A prolific author and energetic lecturer on autism, Dr. Rimland garnered the attention of Hollywood who invited him to serve as primary technical advisor to the 1988 movie "Rain Man", in which Dustin Hoffman’s character portrayed the disorder, thereby initiating a global awareness of autism at a time when it was not nearly as prevalent as it is today. Although Dr. Rimland was often at odds with the conventional medical establishment, to this day the ARI data bank, which Dr. Rimland created, remains the world’s largest data bank on autism, containing over 40,000 detailed case histories of autistic children from more than 60 countries. Dr. Rimland’s 1964 book, "Infantile Autism: The Syndrome and Its Implications for a Neural Theory of Behavior", remains a seminal, ground-breaking book in the field, and is credited by many with having changed the prevailing medical view of autism at that time from a disorder that was regarded as purely psychiatric in nature, to one that is now recognized as being distinctly biological.

Families of autistic individuals who are interested in donating cells to the CHOC for study under the NIH grant should contact CHOC directly for further information.

2009-08-11T00:00:00+00:00August 11th, 2009|Autism, News, Stem Cell Research, Stem Cells, Uncategorized|

Bangor Family Heads to Central America for Adult Stem Cell Therapy

Kenneth Kelley, an eight-year old child from the Bangor area will be the first person from Maine to receive adult stem cell therapy for autism. Stem cell therapy for the treatment of autism has been performed in many North American children who have traveled to the ICM clinic in Central America, with several news reports of patient improvements, and one scientific publication from the group supporting the rationale for this therapy (Ichim et al. Stem Cell Therapy for Autism. 2007 Jun 27;5:30).

Autism is a disorder of the brain that occurs as a child is growing up, and is associated with repetitive behavior, lack of ability to interact socially, and impaired communication skills. To date there is no cure for autism, although a variety of experimental interventions are being performed with varying degrees of success.
Adult stem cell therapy for autism is based on the idea that a chronic inflammatory condition in the gut of autistic children may resolve or at least diminished from the healing effects of the mesenchymal stem cells. The other stem cell type that is used for treatment of autism comes from the cord blood. Cord blood stem cells have been demonstrated by numerous American and international scientific groups to secrete factors that promote healing of nerves and enhance oxygenation of the brain.

Marty Kelly, mother of Kenneth, like many parents of autistic children, initially could not believe the diagnosis of autism. Kenneth was 2 years old when his doctors made the diagnosis, which is believed to be made in as many as 1 in 144 children. Marty Kelly, determined to do something about it, arranged for Kenneth to start receiving hyperbaric oxygen treatments for her son, which caused an improvement in his condition. According to her:

"One of the first things we did was buy a hyperbaric oxygen chamber and within a couple of days, he actually sat down and traced the alphabet from A to Z by himself which was huge. First time he’d ever done that."

Hyperbaric oxygen increases growth factor production in the brain, as well as, by providing oxygen theoretically overcomes some of the problems reported in autistic children such as poor oxygenation of certain parts of the brain. In the case of Kenneth, while there were improvements, these were not cures and the underlying condition still caused significant suffering in the Kelley household:

"It’s really hard because he just we can’t go anywhere and we can’t have anyone over. He just screams all day."

Marty is confident adult stem cell therapy will cause benefits in Kenneth based on knowledge of previous children who have been treated with varying degrees of success.

To discuss and learn more about adult stem cell therapy for autism, an Autism Biomedical support group is being created. The first meeting is july 18th at 10 am. To learn more, call 942-2459.

Click the play button in the video below to watch a news report of another autistic child treated with stem cells.

2009-07-08T00:00:00+00:00July 8th, 2009|Autism, News, Stem Cell Research, Stem Cells, Uncategorized|